Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy looking at “disrupting” the cancer treatment market

Nicolas Serandour, chief operating officer (COO) and chief finance officer (CFO) Advanced Oncotherapy (LON:AVO), says the firm is looking at “disrupting the market” with its proton cancer treatment technology.

Serandour says: “We are in the business of treating cancer through radiotherapy but we are using – not X rays – but proton particles”.

The company is developing its cancer treating proton LIGHT proton therapy system, which accelerates protons to levels seen in previous machines but in a unit that is smaller and between a quarter and a fifth of the cost.

 “X rays are great at killing tumours but unfortunately because they are very light particles that are difficult to control, they also hit the tissue before and after the tumour,” he adds, noting that protons can attack the tumour without affecting the healthy tissue, but have, until now, been seen as too expensive by hospitals.

 
Meet FERRUM CRESCENT LIMITED, Medusa Mining Limited, Wishbone Gold PLC and Condor Gold PLC at our event, London, 08 September 2016. Register here »
Juliet.jpg
Why Invest In Advanced Oncotherapy? Read More Here

Register here to be notified of future Advanced Oncotherapy articles
View full AVO profile

Advanced Oncotherapy Timeline

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.